NasdaqGS:JAZZ

Stock Analysis Report

Executive Summary

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.

Snowflake

Fundamentals

Undervalued with solid track record.


Similar Companies

Share Price & News

How has Jazz Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.9%

NasdaqGS:JAZZ

2.3%

US Pharmaceuticals

2.9%

US Market


1 Year Return

-21.0%

NasdaqGS:JAZZ

-5.8%

US Pharmaceuticals

0.2%

US Market

JAZZ underperformed the Pharmaceuticals industry which returned -6.8% over the past year.

JAZZ underperformed the Market in United States of America which returned -0.7% over the past year.


Share holder returns

JAZZIndustryMarket
7 Day1.9%2.3%2.9%
30 Day0.2%-1.0%-2.3%
90 Day-2.1%-3.6%3.1%
1 Year-21.0%-21.0%-3.5%-5.8%2.4%0.2%
3 Year5.1%5.1%11.3%3.7%41.7%32.4%
5 Year-17.7%-17.7%23.3%10.3%55.1%37.9%

Price Volatility Vs. Market

How volatile is Jazz Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jazz Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

40%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Jazz Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Jazz Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Jazz Pharmaceuticals is good value based on earnings compared to the US Pharmaceuticals industry average.

Jazz Pharmaceuticals is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Jazz Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

Jazz Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Jazz Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

2.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Jazz Pharmaceuticals's revenue is expected to grow by 5.4% yearly, however this is not considered high growth (20% yearly).

Jazz Pharmaceuticals's earnings are expected to grow by 2.7% yearly, however this is not considered high growth (20% yearly).

Jazz Pharmaceuticals's revenue growth is positive but not above the United States of America market average.

Jazz Pharmaceuticals's earnings growth is positive but not above the United States of America market average.

Jazz Pharmaceuticals's earnings growth is positive but not above the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Jazz Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Jazz Pharmaceuticals performed over the past 5 years?

25.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Jazz Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.

Jazz Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (51.1% vs 25.7%)

Jazz Pharmaceuticals's earnings growth has exceeded the US Pharmaceuticals industry average in the past year (51.1% vs 24.3%).


Return on Equity

Jazz Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Jazz Pharmaceuticals used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Jazz Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Jazz Pharmaceuticals's financial position?


Financial Position Analysis

Jazz Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Jazz Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Jazz Pharmaceuticals's level of debt (53.7%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (93.5% vs 53.7% today).

Debt is well covered by operating cash flow (49.3%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 10.6x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Jazz Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Jazz Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Jazz Pharmaceuticals has not reported any payouts.

Unable to verify if Jazz Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Jazz Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Jazz Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Jazz Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Bruce Cozadd (55yo)

10.3yrs

Tenure

US$11,443,133

Compensation

Mr. Bruce C. Cozadd co-founded Jazz Pharmaceuticals Public Limited Company (also known as Jazzpharmaceuticals, Inc.) in 2003 and has been Chairman and Chief Executive Officer since April 2009. Mr. Cozadd s ...


CEO Compensation Analysis

Bruce's remuneration is higher than average for companies of similar size in United States of America.

Bruce's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.2yrs

Average Tenure

56yo

Average Age

The average tenure for the Jazz Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.3yrs

Average Tenure

58.5yo

Average Age

The tenure for the Jazz Pharmaceuticals board of directors is about average.


Insider Trading

Jazz Pharmaceuticals individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$600,58914 Aug 19
Paul Treacy
EntityIndividual
Role
Chief Technology Officer
Senior Vice President of Technical Operations
Shares4,371
Max PriceUS$137.40
SellUS$98,48112 Aug 19
Patrick Enright
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares726
Max PriceUS$135.65
SellUS$98,48212 Aug 19
Rick Winningham
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares726
Max PriceUS$135.65
SellUS$98,48212 Aug 19
Catherine Sohn
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares726
Max PriceUS$135.65
SellUS$110,82512 Aug 19
Elmar Schnee
EntityIndividual
Shares817
Max PriceUS$135.65
SellUS$98,48212 Aug 19
Norbert Riedel
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares726
Max PriceUS$135.65
SellUS$98,48212 Aug 19
Kenneth O’Keefe
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares726
Max PriceUS$135.65
SellUS$106,75612 Aug 19
Heather McSharry
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares787
Max PriceUS$135.65
SellUS$106,75712 Aug 19
Peter Gray
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares787
Max PriceUS$135.65
SellUS$98,48112 Aug 19
Paul Berns
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares726
Max PriceUS$135.65
SellUS$143,53508 Mar 19
Paul Treacy
EntityIndividual
Role
Chief Technology Officer
Senior Vice President of Technical Operations
Shares1,060
Max PriceUS$135.41
SellUS$121,92305 Mar 19
Paul Treacy
EntityIndividual
Role
Chief Technology Officer
Senior Vice President of Technical Operations
Shares874
Max PriceUS$139.50
BuyUS$7,228,00119 Nov 18
Seamus Mulligan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$145.05

Ownership Breakdown


Management Team

  • Bruce Cozadd (55yo)

    Co-Founder

    • Tenure: 10.3yrs
    • Compensation: US$11.44m
  • Karen Wilson (56yo)

    Senior VP of Finance & Principal Accounting Officer

    • Tenure: 7.6yrs
    • Compensation: US$1.24m
  • Dan Swisher (56yo)

    President & COO

    • Tenure: 1.6yrs
    • Compensation: US$5.75m
  • Mike Miller (62yo)

    Executive Vice President of US Commercial

    • Tenure: 5.3yrs
    • Compensation: US$2.86m
  • Matt Young (50yo)

    Executive VP & CFO

    • Tenure: 5.4yrs
    • Compensation: US$3.36m
  • Kathee Littrell

    Vice President of Investor Relations

    • Tenure: 0.0yrs
  • Paul Treacy (58yo)

    Senior Vice President of Technical Operations

    • Tenure: 5.1yrs
  • Allen Yang

    Head of Clinical Development & Acting Chief Medical Officer

    • Tenure: 0.0yrs
  • Neena Patil

    General Counsel

    • Tenure: 0.1yrs
  • Heidi Manna

    Senior VP & Chief Human Resources Officer

    • Tenure: 0.8yrs

Board Members

  • Ken O’Keefe (52yo)

    Independent Director

    • Tenure: 15.6yrs
    • Compensation: US$546.92k
  • Bruce Cozadd (55yo)

    Co-Founder

    • Tenure: 10.3yrs
    • Compensation: US$11.44m
  • Seamus Mulligan (59yo)

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: US$554.42k
  • Peter Gray (64yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$569.42k
  • Norbert Riedel (61yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$566.92k
  • Patrick Enright (58yo)

    Independent Director

    • Tenure: 10.1yrs
    • Compensation: US$559.42k
  • Paul Berns (52yo)

    Independent Director

    • Tenure: 9.6yrs
    • Compensation: US$544.42k
  • Rick Winningham (59yo)

    Lead Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$591.92k
  • Cathy Sohn (66yo)

    Independent Director

    • Tenure: 7.1yrs
    • Compensation: US$554.42k
  • Heather McSharry (57yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$579.42k

Company Information

Jazz Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jazz Pharmaceuticals plc
  • Ticker: JAZZ
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.579b
  • Shares outstanding: 56.62m
  • Website: https://www.jazzpharma.com

Number of Employees


Location

  • Jazz Pharmaceuticals plc
  • Waterloo Exchange
  • Fifth Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JAZZNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2007
J7ZDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2007

Biography

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 00:01
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.